Biotech Intel

Latest Comments

Commercialising graphene: Graphene oxide biosensors

April 24, 2017
| April 24, 2017

What is a biosensor? Ladies, bear with me for a minute. Prostate cancer is the most common cancer in men […]

BlueOcean in position to tap three huge markets with antioxidant

February 21, 2017
| February 21, 2017

BlueOcean NutraSciences Inc. (TSXV: BOC) announced that it will restart its dormant algae gas infusion subsidiary targeting commercial Omega-3 and […]

IntelGenx takes migraine medication “head-on”

December 22, 2016
| December 22, 2016 | 1 Comment

The term a “bitter pill to swallow” may have been used as a figure of speech since the 17th century, […]

BlueOcean to tap “three huge markets” with the benefits of cannabis and sea

December 14, 2016
| December 14, 2016 | 1 Comment

BlueOcean NutraSciences Inc. (TSXV: BOC) has developed a science-based approach to leverage its current access to 63 retail stores and […]


André Godin on the IntelGenx license for Tadalafil erectile dysfunction dosing patent

December 06, 2016
| December 06, 2016

Andre Godin, Executive Vice President and CFO of IntelGenx Technologies Corp. (TSXV: IGX | OTCQX: IGXT), in an interview with […]

IntelGenX changing delivery of famous erectile dysfunction drug

November 22, 2016
| November 22, 2016 | 4 Comments

IntelGenX Technologies Corp. (TSXV: IGX | OTCQX: IGXT) announced the signing of a binding term sheet for a license to […]

IntelGenx Technologies Corp.